Pharmaceuticals : The price of failure | The Economist
▻http://www.economist.com/news/business/21635005-startling-new-cost-estimate-new-medicines-met-scepticism-price-f
Among those rejecting this new figure as highly misleading are Médecins Sans Frontières, a charity, and the Union for Affordable Cancer Treatment, a patients’ group.
The main point of controversy over such estimates is that they roll in the costs of those drugs that failed to win approval and, for good measure, the cost of capital required for the R&D. Tufts’s estimate includes $1.2 billion for the return on capital forgone while a drug is in development, on the assumption it would have otherwise earned a generous 10.5% a year. The remaining $1.4 billion is the average R&D cost of a random selection of drugs, multiplied by risk factors that account for the chances of failure at each stage.
#big_pharma #coûts #mensonges #r&d #cancer
Je fais partie de ce groupe UACT nouvellement créé pour lutter contre le prix exorbitant des médicaments anticancéreux : ►http://cancerunion.org